newsfilter
← Latest News
GlobeNewswire·

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3